Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAL02 in severe community-acquired bacterial pneumonia
NCT05776004Phase 2Active, not recruiting
- Sponsor
- Eagle Pharmaceuticals
- Start
- Jul 2023
- Primary completion
- Feb 2026
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 19
01
Overview
Phase 2, randomised, double-blind trial in community-acquired bacterial pneumonia (CAP) comparing CAL02 with Standard of Care with Placebo with Standard of Care (2 arms). Primary endpoints: Clinical Recovery at 28 days and Treatment-Emergent Adverse Events at 28 days. Started Jul 2023; status: active, not recruiting.
02
Drugs
CAL02
03
Conditions
community-acquired bacterial pneumonia (CAP)
Beyond the preview
Go deeper on NCT05776004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05776004.